2nd Annual European Neoantigen Summit is organized by Hanson Wade and will be held during Apr 24 - 26, 2018 at Postillion Convention Center Amsterdam, Amsterdam, Noord Holland, Netherlands.
The target audience for this medical event is Biotech, Large Pharma, Academics Looking to Network with Industry, Tumour Sequencing and Bioinformatics Service Providers, CMOs, CROs.
This Summit is focused on supercharging tumor targeting through the identification, prediction, and utilization of the most cutting-edge neoantigen strategies. Join the leaders across pharma and biotech to discuss how the current in silico methods for identifying neoantigens will spur on the next generation of personalized cancer immunotherapies.
- Build a commercial roadmap for the manufacture of personalized therapies at scale and navigate the regulatory minefield to understand how to develop and deliver clinical trials for regulatory approval.
- Meet the experts in the field in Amsterdam to analyze the approaches being utilized to measure peptide binders of MHC molecules to improve algorithm accuracy, providing the strongest foundation on which to advance your drug development programme.
- Ensure that immunogenic neoantigens become the rule rather than the exception, bringing personalized cancer immunotherapies to new heights.
"This meeting was the most comprehensive survey of the emerging field of neoantigen-based therapeutics with excellent speakers" - Argos Therapeutics
Industry Conference + 2 Workshops: EUR 3197
Industry Conference + 1 Workshop: EUR 2698
Industry Conference Only: EUR 2199
Workshop Only (each)1: EUR 599
Solutions Provider Conference + 2 Workshops: EUR 4397
Solutions Provider Conference + 1 Workshop: EUR 3798
Solutions Provider Conference Only: EUR 3199
Workshop Only (each)2: EUR 699
Speakers: Executive Director - Inflammation, Amgen, Head of Bioinformatics - TRON, CSO - Aduro Europe, Senior Project Manager - BioNTech, CSO - Vaccibody, Senior Scientist and Project Manager Inflammation - Amgen, COO - VAXIMM GmbH, Speaker TBC – Personalis, Founder and CTO - Immatics Biologics, Immunopeptidomics Unit, Center of Experimental Therapeutics - Department of Oncology - UNIL/CHUV, Professor, Group leader Immunoinformatics and Machine-Learning - Center for Biological Sequence Analysis - The Technical University of Denmark, Assistant Professor of Oncology, Centre of Immunotherapy - Roswell Park Cancer Centre, Program Manager - Parker Institute for Cancer Immunotherapy, Professor – CHUV, Director - Centre for Innovations in Medicine, Biodesign Institute - Arizona State University
Additional details will be posted as soon as they are available.